Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effect of colchicine on mortality in patients with COVID-19 — A systematic review and meta-analysis

Ahmad Fariz Malvi Zamzam Zein a, b, *, Wilson Matthew Raffaello c

a Department of Internal Medicine, Faculty of Medicine, Universitas Swadaya Gunung Jati, Cirebon, Indonesia
b Department of Internal Medicine, Waled General Hospital, Cirebon, Indonesia
c Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia

Abstract

Background and aim: This systematic review and meta-analysis aimed to evaluate the latest evidence on the association between colchicine and mortality in patients with COVID-19.

Methods: We performed a comprehensive literature search from the PubMed, Scopus, Embase, EuropePMC, and Clinicaltrials.gov up until 02 January 2022. We include randomized controlled trials (RCTs) and observational studies reporting colchicine use in patients with COVID-19 and mortality within 30 days. The intervention group was patients given colchicine during the course of treatment. The control group was patients given placebo or standard of care at the respective institutions. The outcome was mortality. The effect estimate was reported as risk ratio (RR).

Results: There were 12 studies comprising of 6953 patients included in this meta-analysis. Mortality rate was 0.18 [95%CI 0.10, 0.26] in the colchicine group and 0.26 [95%CI 0.15, 0.38] in the control group. Colchicine was associated with reduction in mortality (RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I²: 42%). Sensitivity analysis using fixed-effect model (RR 0.73 [95%CI 0.63, 0.83], p < 0.001; I²: 42%). Subgroup analysis on the four RCTs showed non-significant result (RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I²: 10%). Meta-regression showed that the association between colchicine and reduced mortality was not affected by age (p = 0.613) [Fig. 3], sex (p = 0.915), diabetes (p = 0.795), and hypertension (p = 0.403).

Conclusion: Though the meta-analysis showed decreased mortality with colchicine in patients with COVID-19, the meta-analysis of randomized trials did not show any significant effect of colchicine on mortality.

1. Introduction

COVID-19 contributed to death directly and indirectly [1,2]. The search of effective, safe, and inexpensive drug for improving COVID-19 outcome continues; this usually involve repurposing medications that were widely known. Although most of medications were promising at first, many of them was found to be of no benefit in larger randomized controlled trials (RCTs) [3]. Many drugs were used off-label for treating COVID-19 [4–6], one of them is colchicine, which is a well-known anti-inflammatory agents that is approved by FDA to be used to treat gout arthritis and Familial Mediterranean fever and it is also used as an off-labeled drug against pseudogout, sarcoid and psoriatic arthritis, Bechet’s disease and pericarditis [7–9].

The true nature of colchicine remains elusive, however due to its modulatory effect on inflammatory response and its possible antiviral properties, as well as small studies showing promising results [10,11], colchicine is worth to be studied further. This systematic review and meta-analysis aimed to evaluate the latest evidence on the association between colchicine and mortality in patients with COVID-19.

2. Methods

This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline.
2.1. Search strategy and study selection

We performed a comprehensive literature search from the PubMed, Scopus, Embase, EuropePMC, and Clinicaltrials.gov for “(2019-nCoV OR COVID-19 OR SARS-CoV-2) AND (colchicine)” from the beginning of time until 02 January 2022. Title/abstract screening and eligibility assessment of the full-text articles were performed by two independent authors. Discrepancies during the process were resolved by discussion.

2.2. Inclusion and exclusion criteria

Studies that fulfill the following criteria were included: 1) RCTs and observational studies reporting colchicine use in patients with COVID-19 and 2) mortality within 30 days.

Studies that fulfill one of the following criteria were excluded: 1) editorial/commentaries, 2) conference papers, 3) review articles, 4) letters, and 5) abstracts. There was no language restriction.

2.3. Intervention and outcome

The intervention group was patients given colchicine during the course of treatment. The control group was patients given placebo or standard of care at the respective institutions. The outcome was mortality. The effect estimate was reported as risk ratio (RR).

2.4. Data extraction

Data from the eligible studies were extracted by two independent authors using standardized extraction form that contain the author of the studies, study design, inclusion criteria, colchicine regimen, control group, sample size, age, sex, comorbidities, and the mortality in the intervention and control groups. Discrepancies during the process were resolved by discussion.

2.5. Risk of Bias Assessment

Risk of bias assessment was performed by two independent authors with two tools, Newcastle-Ottawa Scale (NOS) [12] for non-randomized studies and Cochrane Risk of Bias Assessment for RCTs [13]. Discrepancies during the process were resolved by discussion.

2.6. Statistical analysis

Random-effects meta-analysis using the Mantel-Haenszel statistical method was performed to pool the effect of colchicine on mortality compared to the control group using the dichotomous values. We used random-effects model regardless of heterogeneity considering the variation in doses, and fixed-effects model was performed during the sensitivity analysis. Subgroup analysis was performed for RCTs and published studies. P-values of \( p < 0.05 \) were considered as statistically significant. Interstudy heterogeneity was evaluated using the I\(^2\) statistics and a value above 50% and p-
value < 0.10 indicates heterogeneity. Meta-regression analysis was performed using the random-effects restricted maximum likelihood (REML) in order to evaluate whether the effect of colchicine on mortality was influenced by age, sex, diabetes, and hypertension. Review Manager 5.4 and STATA version 16.0 software were used to perform the meta-analysis.

3. Results

3.1. Baseline characteristics

There were 12 studies comprising of 6953 patients included in this meta-analysis [10,11,14–23] [Fig. 1]. There were 4 RCTs and 8 observational studies included in this analysis. García-Posada et al. study reported a group with unclear treatment (treatment: others), which was excluded from our analysis because it may lead to bias. The characteristics of the included studies can be seen in Table 1.

3.2. Colchicine and Mortality

Mortality rate was 0.18 [95%CI 0.10, 0.26] in the colchicine group and 0.26 [95%CI 0.15, 0.38] in the control group. Colchicine was associated with reduction in mortality (OR 0.66 [95%CI 0.53, 0.83], p < 0.001; I²: 42%, p = 0.06) [Fig. 2]. Sensitivity analysis using fixed-effect model (OR 0.73 [95%CI 0.63, 0.83], p < 0.001; I²: 42%, p = 0.06). Subgroup analysis on the four RCTs showed non-significant result (OR 0.81 [95%CI 0.54, 1.20], p = 0.29; I²: 10%, p = 0.34). Subgroup analysis on published studies showed significant reduction in mortality (OR 0.65 [95%CI 0.50, 0.85], p = 0.001; I²: 52%, p = 0.03).

3.3. Meta-regression

The association between colchicine and reduced mortality was not affected by age (p = 0.613) [Fig. 3], sex (p = 0.915), diabetes (p = 0.795), and hypertension (p = 0.403).

3.4. Publication bias

Risk of bias for RCT is in [Fig. 4] and for observational studies is in Table 1. Funnel-plot was asymmetrical with more studies on the left side (more significant) [Fig. 5]. Egger’s test indicated the presence of small-study effects (p = 0.003).

4. Discussion

This meta-analysis showed that colchicine was associated with decreased mortality in patients with COVID-19 with low heterogeneity. The benefit was statistically significant with both random-effects and fixed-effect model. Meta-regression analysis was unable to find the cause of heterogeneity. Nevertheless, we note that the doses were different among the studies, which may cause slight heterogeneity in the effect estimate. We note that there was a presence of small-study effects and publication bias, as evident by the funnel-plot analysis that indicate that asymmetry with more studies in the left side of the plot. Studies with positive results are more likely to be reported and published, which is one of the weaknesses of meta-analysis. Subgroup analysis of RCTs on mortality was not statistically significant, however, it was likely due to small number of events rather than true null result. Although the result remained inconclusive, colchicine is a promising drug that warrants further RCTs to increase the certainty of evidence in order to recommended for routine clinical practice.

Meta-regression analysis was performed to explore potential source of heterogeneity, several comorbidities [24–36] and its associated medications [33,37,38] have been shown to affect mortality in patients with COVID-19, thus may alter the benefit. The meta-regression showed that all covariates we analyzed did not significantly contribute to heterogeneity of the pooled effect estimate.

The history of colchicine itself can be traced back to over 2000 years ago when it was widely used as a poison or as a remedy for gout flares [8]. As a drug that possibly had been discovered in the ancient times and had been used in such an extended period of time, the potential anti-inflammatory and antiviral properties has not been discovered too much. By taking a closer look on the intersection between COVID-19 induced inflammation and colchicine’s effect in regulating inflammatory response might shed a light on a potential use of colchicine in COVID-19.

The possible inhibitory effect of colchicine towards COVID-19 might relies on its inhibition on microtubule assembly, and its inflammatory regulation properties. Microtubules, which is a key component of the cytoskeleton, facilitates the movement of adhesion molecules onto the cell surface during inflammation [39]. It also affected by the colchicine which binds to the soluble tubulin heterodimer and it will eventually forms a tubulin-colchicine complex [9]. The interaction between each molecules shows a dose-dependent response which is lower at lower dose. It interferes microtubule formation and elongation, and in higher dose, it promotes microtubule depolymerization [40]. Consequently, these events might lead to microtubule distortion and leading to possible disruption of cell metabolism such as division, signal transduction, integrity, and transport system [8].

As demonstrated in Dengue virus and Zika virus, Colchicine shows a significant decrease of intracellular viral replication, possibly due to the micro tubule dependence viral replication and the polymerization of microtubule affected by the colchicine [41]. While coronavirus replication in the cell requires a functional microtubule, interference of microtubule and its associated protein might impaired the essential microtubule-associated transport and therefore might interfere viral cell replication [42]. In addition to that, the process of coronavirus cell entry might require an interaction between the cytoplasmic tail of the spike protein and a cytoskeletal protein. It is possibly this process might be interrupted due to the colchicine-tubulin complex, however more evidence is required [43].

The anti-inflammatory effect of colchicine is well demonstrated through various inflammatory pathways in which colchicine exert its effect. It capable of decreasing the expression of adhesion molecules on neutrophil membranes, presumably due to the colchicine induced neutrophil adhesion molecules shedding, which will leads to a decrease capability of inflammatory cell migration and helps modulate inflammatory cytokine production such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor – alpha (TNF-α) [9]. In fact, colchicine tends to accumulate in neutrophil, mainly due to the lack of P-glycoprotein membrane efflux pump in neutrophil and therefore reducing the capability of transporting colchicine out from the cell [44]. Due to the accumulation of colchicine in the neutrophil, it causes several disruptions to the neutrophil functions. Intracellular signaling and lysosomal enzyme released during phagocytosis impairment is prominent while it seems colchicine has played a role in the inhibition of calcium influx, which seems also to have an inhibitory effect on platelet activation, and reduce neutrophil response [45]. While it is still under investigation, colchicine seems to be able to decrease cytokine production through the inhibition of novel-like receptor protein 3 (NLRP3) inflammasome activation [46]. This reduces the production of IL-1β which might prevent the induction of other cytokines (IL-6 and TNF) that involve in the process of cytokine storm [47]. COVID-19 was shown to cause endotheliopathy, coagulopathy, hyper-
Table 1
Characteristics of the included studies.

| Authors                  | Design   | Inclusion Criteria                                                                 | Samples | Colchicine Dosing | Control | Age (years) | Male (%) | Diabetes (%) | Hypertension (%) | CAD Follow-up (days) | NOS |
|--------------------------|----------|-------------------------------------------------------------------------------------|---------|------------------|---------|-------------|----------|--------------|---------------------|----------------------|------|
| Brunetti 2020 PSM       | Cohort   | Severe COVID-19                                                                     | 33 vs. 33 | 1.2 mg followed by SOC | 61.7 vs. 64.1 | 63.6 vs. 66.7 | 21.2 vs. 21.2 | 60.6 vs. 36.4 | 21.1 vs. 6.1 | 28 vs 8 | 8 |
| COLCORONA RCT 2021      |          | Age >40 Diagnosed with COVID-19 by PCR within 24 h or direct link with a positive COVID-19 household member or by a clinical algorithm, non-hospitalized patient, at least 1 high risk criteria of: age ≥70, obesity (BMI ≥ 30), diabetes, SBP ≥150, history of respiratory disease, heart failure, coronary disease, fever ≥38.4°C within 48 h, dyspnea at the time of presentation, bicytopenia, pancytopenia, or the combination of high neutrophil and low lymphocyte counts. | 2075 vs. 2084 | 2 × 0.5 mg per day for 30 days | Placebo | 54.4 vs. 54.9 | 44.6 vs. 47.5 | 19.9 vs. 20 | 34.9 vs 20 | 2.9 vs 3.2 | See RoB (Fig. 4) |
| COLORIT PC 2021         |          | Severe COVID-19                                                                     | 21 vs. 22 | 1 mg colchicine during the first 3 days followed by 0.5 mg per day | 61.9 vs. 59.9 | 66.7 vs. 72.7 | 14.3 vs. 9.0 | 66.7 vs. 59.1 | 14.3 vs. 18.2 | 12 vs 7 | 7 |
| ECLA PHRI RCT COLCOVID 2021 |      | Moderate to Severe COVID-19                                                         | 640 vs. 639 | 1.5 mg + 0.5 mg followed by 2 × 0.5 mg per day | 62 vs. 62 | 65.8 vs. 64 | 21.8 vs. 23.6 | 48.8 vs. 46.6 | 7.7 vs 6.6 | 28 vs 16.4 | See RoB (Fig. 4) |
| GRECCO-19 RCT 2020      |          | Hospitalized adult COVID-19 patients confirmed with RT-PCR, Body temperature ≥37.5°C, ≥ 2 of following: sustained coughing, sore throat, anosmia, and/or ageusia, fatigue and/or tiredness, arterial oxygen partial pressure <95% on room air. | 55 vs. 50 | 1.5 mg + 0.5 mg followed by 2 × 0.5 mg per day until discharge or 14 days | 65 vs. 63 | 60 vs. 56.4 | 24 vs 21 | 50 vs 40 | 10 vs 21 | See RoB (Fig. 4) |
| Garcia-Posada PC 2021   |          | Hospitalized COVID-19                                                               | 113 vs. 44 | Given for 20 days, dose unclear | SOC | NA | NA | NA | NA | NA | 5 |
| Lopes 2021 RCT          |          | Age ≥18, Moderate to severe COVID-19 diagnosed by RT-PCR and CT-scan, Body weight >50 kg, normal serum Ca²⁺ and K⁺, QT interval <250 ms, negative serum or urinary β-HCG if woman <50 years old Age ≥18 yo, Positive COVID-19 by RT-PCR, SOB at rest or with exercise (6-min walk test), room air saturation <94% | 37 vs. 38 | 1.0 mg followed by 3 × 0.5 mg per day | Placebo | 55.0 vs. 39.5 | 53 | 42 vs 36 | NA | 26 | See RoB (Fig. 4) |
| Mahale 2021 RC          |          | COVID-19 patients (hospitalized with pneumonia on CT scan or outpatients)          | 39 vs. 95 | 0.5 mg per day | SOC | 55.6 | 67.9 | 44 | 46 | NA | 7 |
| Manenti RC 2021         |          | Adult patients with COVID-19 Pneumonia confirmed by Real-Time Polymerase Chain Reaction for SARS-CoV-2 and Radiological Findings | 70 vs. 71 | 1 mg per day up to 21 days | SOC | 60.5 vs. 62.5 | 72.9 vs 69 | 15.7 vs. 18.3 | 55.7 vs 60.6 | NA | 21 | 8 |
| Pinzon 2021 PC          |          | Age ≥18, Confirmed COVID-19 by PCR, hospitalized,                                  | 145 vs. 156 | 2 × 0.5 mg per day for 7–14 days | Placebo | 57.2 | 59.1 | 24.3 | 45.5 | 6.0 | Until 7 Discharge |
| Sandhu 2020 PC          |          | Virologically and radiographically confirmed COVID-19 patients hospitalised         | 34 vs. 78 | 2 × 0.6 mg per day for 12 days | Placebo | 67.7 vs 66.4 | 61.8 vs 51.3 | 32.4 vs 51.3 | 52.9 vs 71.8 | 5.9 vs 7.7 | Until 7 Discharge |
| Scarsi 2020 PC          |          | Virologically and radiographically confirmed COVID-19 patients hospitalised         | 122 vs. 140 | 1.0 mg per day | SOC | 69.3 vs 70.5 | 63 vs 64 | NA | NA | 21 vs 8 | 7 |

CAD: Coronary Artery Disease, PC: Prospective Cohort, PSM: Propensity-Score Matched; RC: Retrospective Cohort, RCT: Randomized Controlled Trial, RoB: Risk of Bias, NA: Not Available, NOS: Newcastle-Ottawa Scale, COVID-19: Coronavirus Disease-2019, CT-scan: Computed Tomography-Scan, PCR: Polymerase Chain Reaction, SARS-CoV-2: Severe Acute Respiratory Symptoms Coronavirus 2, SOB: Shortness of Breath, β-HCG: β Human Chorionic Gonadotropin, ms: Millisecond, kg: Kilogram, BMI: Body Mass Index, SBP: Systolic Blood Pressure.

* Group with unclear treatment (treatment: others) was excluded from the analysis because it may lead to bias.

result, to sufficiently conclude additional RCTs are required. The doses were heterogeneous, trials comparing multiple dose are also required to obtain the optimum dosage.

5. Conclusion

Though the meta-analysis showed decreased mortality with colchicine in patients with COVID-19, the meta-analysis of randomized trials did not show any significant effect of colchicine on inflammation, and cytokine storm that may potentially cause end-organ damage [48–55,55–64]. Therefore, the anti-inflammatory and platelet inhibitory properties of colchicine that involved various steps of inflammatory response may potentially alleviate the pathology and improve outcome.

This meta-analysis has several limitations; publication bias is commonly encountered in meta-analysis because positive studies are more likely to be reported compared to negative studies. There were only three RCTs in this pooled analysis, with inconclusive
Funding
None.

Ethical approval
Not Applicable.

Informed consent
Not Applicable.

Data availability
Data are available on reasonable request.

Contributorship statement
AFMZZ was involved in the conceptualization and design of the manuscript. AFMZZ and WMR participated in data curation and investigation. AFMZZ performed formal and statistical analysis. AFMZZ and WMR drafted the manuscript. AFMZZ and WMR review and edited the manuscript.

Declaration of competing interest
None.
